Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMAZE 4 trial of once-weekly subcutaneous NNC0487-0111 in overweight or obese adults with obstructive sleep apnea receiving positive airway pressure therapy
CTR20262570Phase 3Active
- Sponsor
- Novo Nordisk
- Start
- Sep 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of amycretin in obesity, Overweight, obstructive sleep apnea hypopnea syndrome (OSAHS), sponsored by Novo Nordisk. Started Sep 2026; status: active.
02
Drugs
amycretin
03
Conditions
obesityOverweightobstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on CTR20262570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262570.